Occurrence of mental disorders in nonspecific inflammatory boweldiseases: a primary or secondary problem in relation to the biologicaltherapy used?
DOI:
https://doi.org/10.2478/cpp-2020-0022Keywords:
colitis ulcerosa, Crohn disease, depression, mental disorders, inflammatory bowel diseaseAbstract
Introduction: Nonspecific inflammatory bowel diseases include Crohn’s disease (CD) and ulcerative colitis (CU – colitis ulcerosa), which are chronic diseases characterized by periods of exacerbation and remission. Extraintestinal complications caused by the disease and the applied treatment, mainly steroid therapy, constitute a predisposition to infections and mental disorders such as depressive disorders with apathy, slowness of movement or agitation, and even manic syndromes.
Aim and method: The aim of this study was to review the literature on the occurrence of primary and secondary mental disorders in the course of inflammatory bowel diseases. The literature in the Google Scholar database was reviewed using the following keywords: colitis ulcerosa, Crohn disease, depression, mental disorders, inflammatory bowel disease. The time descriptors 2011-2021 were also used.
Conclusions: The review of epidemiological studies shows that the most common mental disorders in nonspecific inflammatory bowel diseases are anxiety and depression disorders. The effect of steroid therapy on the development of mental disorders is equally significant. Most of the available empirical data relating to corticosteroids confirm the correlation between the drugs and depressive symptoms, and other psychiatric effects, including mania and psychosis.
Summary: As with most chronic diseases, the prevalence of anxiety and depression disorders is higher in nonspecific inflammatory bowel diseases than in the general population.
References
1. Grzywa A., Makara-Studzińska M. , Grzywa-Celińska A. Mental disorders and somatic illnesses. Curr Probl Psychiatry 2011; 12(1): 67-72.
2. Graff AL., Walker JR , Bernstein NC. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis. 2009 Jul;15(7):1105-18.
3. Spijker AT , van Rossum EFC.Glucocorticoid Sensitivity in Mood Disorders. Neuroendocrinology 2012;95:179–186.
4. Ménard C. , Pfau ML., Hodes GE. , Russo SJ. Immune and Neuroendocrine Mechanisms of Stress Vulnerability and Resilience. Neuropsychopharmacology volume 42, pages62–80(2017).
5. Nowakowski J. ,Chrobak AA. , Dudek D. Psychiatric illnesses in inflammatory bowel diseases – psychiatric comorbidity and biological underpinnings. Psychiatr. Pol. 2016; 50(6): 1157–1166.
6. Mahadev S, Young JM, Selby W, Solomon MJ. Self-reported depressive symptoms and suicidal feelings in perianal Crohn’s disease. Colorectal Dis. 2012; 14(3): 331–335.
7. Vigano CA., Betrami MM., Bosi MF., Zanello R., Valtorta M., Maconi G. Alexithymia and Psychopathology in Patients Suffering From Inflammatory Bowel Disease: Arising Differences and Correlations to Tailoring Therapeutic Strategies. Front Psychiatry 2018 Aug 3;9:324.
8. Moraitis AG. , Block T., Nguyen D. , Belanoff JK. The role of glucocorticoid receptors in metabolic syndrome and psychiatric illness. J Steroid Biochem Mol Biol 2017 Jan;165(Pt A):114-120.
9. Panara AJ, Yarur AJ, Rieders B, Proksell S, Deshpande AR, Abreu MT. et al. The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study. Aliment. Pharmacol. Ther. 2014; 39(8): 802–810.
10. Ananthakrishnan AN, Gainer VS, Cai T, Perez RG, Cheng SC, Savova G. et al. Similar risk of depression and anxiety following surgery or hospitalization for Crohn’s disease and ulcerative colitis. Am. J. Gastroenterol. 2013; 108(4): 594–601.
11. Bannaga A, Selinger C. Inflammatory bowel disease and anxiety : links, risks, and challenges faced. Clin. Exp. Gastroenterol. 2015; 8: 111–117.
12. Ananthakrishnan AN, Gainer VS, Perez RG, Cai T, Cheng SC, Savova G. et al. Psychiatric comorbidity is associated with increased risk of surgery in Crohn’s disease. Aliment. Pharmacol. Ther. 2013; 37(4): 445–454.
13. 13. Maconi G, Gridavilla D, Viganò C, Sciurti R, Asthana AK, Furfaro F. et al. Perianal disease is associated with psychiatric co-morbidity in Crohn’s disease in remission. Int. J. Colorectal Dis. 2014; 29: 1285–1290.
14. Abautret-Daly A , Dempsey E , Riestra S, de Francisco-García R, Parra-Blanco A , Rodrigo L , Medina C, Connor TJ, Harkin A. Association between psychological measures with inflammatory anddisease-related markers of inflammatory bowel disease. International Journal of Psychiatry in Clinical Practice, 21:3, 221-230.
15. Keefer L, Kane SV. Considering the bidirectional pathways between depression and IBD: recommendations for comprehensive IBD care . Gastroenterol Hepatol . (2017) 13 : 164–9.
16. Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. J Clin Invest. 2015 Mar 2;125(3):926-38.
17. Fardet L, Flahault A, Kettaneh A, Tiev KP, Généreau T, Tolédano events: frequency, risk factors and patient's opinion. Br J Dermatol. 2007 Jul;157(1):142-8.
18. Abautret-Daly Á, Dempsey E, Riestra S, de Francisco-García R, Parra-Blanco A, Rodrigo L, et al. Association between psychological measures with inflammatory anddisease-related markers of inflammatory bowel disease. Int J Psychiatry Clin Pract. 2017 Sep;21(3):221-230.
19. Anderson, G., Berk, M., Dean, O., Moylan, S. & Maes, M. (2014). Role of Immune-Inflammatory and Oxidative and Nitrosative Stress Pathways in the Etiology of Depression: Therapeutic Implications. CNS DRUGS, 28 (1), pp.1-10.
20. Fardet L,Flahault ZA,Kettaneh ZA, Tiev KP, Généreau T, Tolédano C, Lebbé C, CabaneJ Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion Br J Dermatol. 2007 Jul;157(1):142-8.
21. Patten SB, Neutel CI. Corticosteroid-induced adverse psychiatric effects: incidence, diagnosis and management. Drug Saf. 2000 Feb;22(2):111-22.
22. Bolanos SH,Chan DA,Hanczyc M, Bauer MS, Dhanani N, Brown ES. Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales. Ann Allergy Asthma Immunol. 2004 May;92(5):500-5.
23. Fardet L, Kassar ZA, Cabanejot, Flahault A. Corticosteroid¬induced adverse events in adults: frequency, screening and prevention. Drug Saf. 2007;30(10):861-81.
24. Spijker AT , van Rossum EFC. Glucocorticoid sensitivity in mood disorders. Neuroendocrinology. 2012;95(3):179-86.
25. Yang YL, Lichtenstein GR. Corticosteroids in Crohn's disease. Am J Gastroenterol. 2002 Apr;97(4):803-23.
26. Buchman AL . Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001 Oct;33(4):289-94.
27. Brown ES, Chandler PA. Mood and Cognitive Changes During Systemic Corticosteroid Therapy. Prim Care Companion J Clin Psychiatry. 2001 Feb;3(1):17-21.
28. Mikocka-Walus A, Knowles SR , Keefer L , Graff L. Controversies Revisited: A Systematic Review of the Comorbidity of Depression and Anxiety with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016 Mar;22(3):752-62.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
